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Lack of Fibronectin Extra Domain 
A Alternative Splicing Exacerbates 
Endothelial Dysfunction in Diabetes
Gianluca Gortan Cappellari1, Rocco Barazzoni1, Luigi Cattin1, Andrés F. Muro2 & 
Michela Zanetti1
Glucose-induced changes of artery anatomy and function account for diabetic vascular complications, 
which heavily impact disease morbidity and mortality. Since fibronectin containing extra domain 
A (EDA + FN) is increased in diabetic vessels and participates to vascular remodeling, we wanted 
to elucidate whether and how EDA + FN is implicated in diabetes-induced endothelial dysfunction 
using isometric-tension recording in a murine model of diabetes. In thoracic aortas of EDA−/−, EDA+/+ 
(constitutively lacking and expressing EDA + FN respectively), and of wild-type mice (EDAwt/wt), 
streptozotocin (STZ)-induced diabetes impaired endothelial vasodilation to acetylcholine, irrespective 
of genotype. However STZ + EDA−/− mice exhibited increased endothelial dysfunction compared 
with STZ + EDA+/+ and with STZ + EDAwt/wt. Analysis of the underlying mechanisms revealed that 
STZ + EDA−/− mice show increased oxidative stress as demonstrated by enhanced aortic superoxide 
anion, nitrotyrosine levels and expression of NADPH oxidase NOX4 and TGF-β1, the last two being 
reverted by treatment with the antioxidant n-acetylcysteine. In contrast, NOX1 expression and 
antioxidant potential were similar in aortas from the three genotypes. Interestingly, reduced eNOS 
expression in STZ + EDA+/+ vessels is counteracted by increased eNOS coupling and function. Although 
EDA + FN participates to vascular remodelling, these findings show that it plays a crucial role in limiting 
diabetic endothelial dysfunction by preventing vascular oxidative stress.
Diabetes-associated vascular disease is characterized by endothelial dysfunction and by excess accumulation 
of basement membrane proteins in the subendothelial layer1,2. Fibronectin (FN), a multidomain glycoprotein 
classically involved in the regulation of cell-cell and cell–matrix interactions, has an essential role in diabetic angi-
opathy3,4. FN expression is subject to alternative splicing of the primary transcript at three sites: the cassette-type 
extra domains A (EDA or EIIIA) and B (EDB or EIIIB), and the type III connecting segment, generating up to 
20 different isoforms5,6. Unlike for EDB + FN, several specific functions for EDA + FN in adult subjects have 
recently been described, mainly related to wound healing, tissue fibrosis, thrombosis and vascular wall integ-
rity5–7. EDA + FN inclusion is highly restricted in adult healthy vessels but increases in vascular disease and in 
atherosclerosis8. In this setting, it contributes to plaque enlargement but also to its stabilization9,10. In addition, 
reduced expression of EDA + FN has been associated with thoracic aortic aneurysm formation11 as well as with 
hemorrhage of the vessel wall12. Finally, mice strains devoid of EDA exon regulated splicing show reduced plaque 
formation, indicating EDA splicing as an important broad modulator of atherogenesis13,14.
Diabetes, a well-known risk factor of vascular disease, is associated with enhanced vascular synthesis, plasma 
levels and vascular deposition of EDA- and EDB- expressing FN15,16. These events, which characterize diabetic 
angiopathy, initiate important events in response to injury17. Several studies have shown that transforming growth 
factor beta (TGF-β ), typically activated in diabetic vessels18, is a potent inducer of extracellular matrix deposition 
and of EDA + FN splicing19,20.
Endothelial dysfunction, characterized by increased superoxide production, reduced nitric oxide (NO) bio-
availability and impaired endothelium-dependent dilation, is a hallmark of diabetes1. Hyperglycemia enhances 
NADPH oxidase activity to generate superoxide21, which combines with nitric oxide, to form peroxynitrite. 
Peroxynitrite rapidly oxidizes the eNOS cofactor tetrahydrobiopterin, determining eNOS uncoupling22–24. In 
these conditions, the enzyme actively produces superoxide rather than NO, further contributing to oxidative 
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stress and endothelial dysfunction. In addition, NADPH oxidase-induced eNOS uncoupling mediates extracel-
lular matrix injury and stimulates de-novo FN synthesis24, which in turn negatively modulates eNOS expres-
sion and activity in endothelial cells25. The interaction between EDA + FN, reactive oxygen species (ROS) 
and eNOS is currently unclear and the potential functional role of EDA + FN accumulation in the setting of 
diabetes-associated endothelial dysfunction is unknown.
Results
Animal characteristics, survival, hormonal and metabolic profile. To evaluate the impact of 
EDA + FN alternative splicing on endothelial function during diabetes, we used male mice from two engineered 
mouse strains26 lacking regulated splicing of fibronectin EDA exon, one constitutively including (EDA+/+) and 
the other constitutively excluding the exon (EDA−/−), due to the optimization of the EDA splicing sites and to the 
targeted deletion of the EDA exon, respectively. Baseline body weight and glucose were comparable in EDA+/+, 
EDA−/− and EDAwt/wt mice. Basal insulin levels tended to be higher (p < 0.05) in EDAwt/wt, while still in physio-
logical range27 (Table 1). STZ treatment resulted in sustained blood glucose concentration of > 18 mmol/liter in 
> 90% of mice without differences among genotypes. At 16 weeks after treatment, STZ-induced diabetic mice 
showed reduced body weight and plasma insulin compared to control (Table 1).
Constitutive exclusion of EDA domain increases endothelial dysfunction to acetylcholine in 
STZ-treated mice without modifying endothelium-independent dilation to DEA-NONOate. 
Isometric tension recording studies in organ chambers demonstrated that submaximal contractions to phenyle-
phrine were similar in aortas from diabetic and non-diabetic EDAwt/wt, EDA+/+ and EDA−/− mice. Aortas from 
non-diabetic animals showed similar relaxations to acetylcholine (Fig. 1a). STZ treatment resulted in impaired 
Control STZ
EDAwt/wt EDA+/+ EDA−/− EDAwt/wt EDA+/+ EDA−/−
n 26 30 28 43 44 40
Body weight (g)
Week 0 27.5 ± 0.8a 27.4 ± 0.6a 26.8 ± 0.8a 27.6 ± 0.5a 25.9 ± 1.0a 26.1 ± 0.4a
Week 16 35.2 ± 0.7a* 34.4 ± 0.4a* 33.3 ± 0.7a* 28.6 ± 0.6b 29.5 ± 0.8b 26.6 ± 0.5c
Blood glucose (mmol/l)
Week 0 8.0 ± 0.3a 8.4 ± 0.2a 8.3 ± 0.4a 7.8 ± 0.3a 8.4 ± 0.4a 8.4 ± 0.4a
Week 16 8.3 ± 0.3a 9.1 ± 0.3a 9.0 ± 0.3a 24.7 ± 0.9b* 23.3 ± 1.1b* 23.0 ± 1.6b*
Insulin (μ g/L)
Week 16 0.87 ± 0.1a 0.53 ± 0.08b 0.52 ± 0.07b 0.34 ± 0.04c 0.33 ± 0.03c 0.30 ± 0.05c
Table 1.  Animal phenotype. EDA: Extra Domain A; STZ: streptozotocin-treated. For each time point, data 
sharing the same letter do not differ significantly; *p < 0.05 vs. week 0.
Figure 1. (a) Endothelium-dependent vasodilation to acetylcholine is impaired in diabetic (STZ+ ) EDA−/− 
mice. Diabetes reduced endothelium-dependent dilation in all animal genotypes, however, STZ + EDA−/− mice 
showed increased endothelial dysfunction compared with STZ + EDAwt/wt and STZ + EDA+/+. In contrast 
endothelium-independent vasodilation to the NO donor DEA-NONOate (b) was similar in control (STZ-) 
and diabetic EDAwt/wt, EDA+/+ and EDA−/− mice suggesting preserved arterial smooth muscle function. Data 
represent at least 7 mice per group. STZ: streptozotocin; $p < 0.05 non diabetic vs. STZ; *p < 0.05 STZ + EDA−/− 
vs. STZ + EDAwt/wt and STZ + EDA+/+.
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endothelium-dependent dilation to acetylcholine in all animal genotypes as expected (Fig. 1a). However, 
STZ + EDA−/− mice showed increased (p < 0.05) endothelial dysfunction compared with STZ + EDAwt/wt and 
STZ + EDA+/+ (Fig. 1a), suggesting reduced NO bioavailability. Endothelium-independent vasodilation to 
DEA-NONOate did not differ among groups, both under euglycemic and hyperglycemic conditions (Fig. 1b).
Total fibronectin levels and eNOS expression and coupling state are preserved in EDA−/− diabetic 
aorta. Total fibronectin levels were comparable between aortas within both control and diabetic genotypes, 
with STZ treated groups showing a trend for increased protein deposition, in agreement with reports in humans 
and in rodent diabetic models28,29 (Fig. 2a and d). To assess whether endothelial dysfunction in STZ + EDA−/− 
mice was related to decreased eNOS expression, total eNOS protein levels were measured in aortas from control 
and diabetic mice. In our model, STZ was associated with lower total eNOS protein levels30 in all genotypes with 
neither significant differences among genotypes of the non-diabetic control animals, nor between STZ + EDA−/− 
and STZ + EDAwt/wt samples (Fig. 2b and d). Accordingly, eNOS dimer/monomer ratio, an accepted marker of 
eNOS uncoupling and function, was similar in EDA−/− and in EDAwt/wt both in control and diabetic conditions 
(Fig. 2c and d). Unexpectedly, during diabetes eNOS protein further decreased by 60% in STZ + EDA+/+ com-
pared with STZ + EDA−/− and STZ + EDAwt/wt (p < 0.05) (Fig. 2b and d). However, this change was compensated 
by increased (p < 0.05) enzyme coupling, as demonstrated by higher eNOS dimer/monomer ratio in this group 
(Fig. 2c and d). To confirm these data, we performed analysis of eNOS-derived superoxide in vessels from control 
and diabetic mice. Incubation of aortic rings with L-arginine, a substrate of NOS, as well as with the competitive 
inhibitor L-NMMA, did not produce different effects on superoxide generation in aortic rings among control 
groups and in STZ + EDA−/− compared to STZ + EDAwt/wt mice (Fig. 2e and f). Instead, in STZ + EDA+/+ mice 
superoxide generation was lowered (p < 0.05) by L-arginine and increased (p < 0.05) by L-NMMA treatments 
(p < 0.05), confirming increased (p < 0.05) eNOS coupling state in this group (Fig. 2e and f). These data support 
the hypothesis of a compensatory mechanism resulting in similar NO production, functionally confirmed by the 
lack of differences in endothelial function between diabetic EDA+/+ and EDAwt/wt groups (Fig. 1a).
Increased endothelial dysfunction in STZ + EDA−/− mice is associated with increased vascular 
ROS and nitrotyrosine generation in the presence of preserved antioxidant potential. We then 
focused our attention on dissecting the mechanisms underlying endothelial dysfunction in STZ + EDA−/− mice 
by investigating ROS generation and redox balance. Aortic ROS generation was directly assessed by measuring 
Figure 2. Expression of total fibronectin and protein levels, coupling state and function of eNOS in aortas 
from diabetic (STZ+) EDA−/−, EDA+/+ and EDAwt/wt compared with control (STZ-) mice. Relative protein 
expression of total fibronectin (a), eNOS (b) and eNOS dimer to monomer ratio (c), with representative blots (d). 
Superoxide generation in aortic rings of control and diabetic mice in the presence of either the NOS substrate 
L-arginine (1 mmol/l) (e) or the enzyme inhibitor L-NMMA (100 μ mol/l) (f). Data are normalized to parietal 
surface and represent at least 7 mice per group. STZ: streptozotocin; OD: Optical Density; RLU: relative light 
units. *p < 0.05 vs other groups with same STZ treatment; #p < 0.05 vs. STZ- groups.
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tissue superoxide production using SOD-inhibitable cytochrome c reduction and lucigenin-enhanced chemi-
luminescence. In control animals superoxide production as assessed by cytochrome c reduction was lower 
(p < 0.05) in aortas from EDA−/− mice, however these data were not confirmed by lucigenin-enhanced chemilu-
minescence (Fig. 3a and b). Importantly, during diabetes superoxide production increased (p < 0.05) in the three 
genotypes according to both methods (Fig. 3a and b). However, STZ + EDA−/− demonstrated higher vascular 
superoxide production than STZ + EDAwt/wt and STZ + EDA+/+ (Fig. 3a and b). Protein tyrosine nitration, result-
ing from superoxide combining with NO was also measured. STZ + EDA−/− exhibited the highest 3-nitrotyrosine 
concentrations among groups (Fig. 3c).
To verify that these findings were due to enhanced superoxide production rather than reduced antioxidant 
potential, antioxidant expression and activity were measured in aortas from experimental animals. There were 
no differences in aortic protein expression of copper/zinc superoxide dismutase (CuZnSOD) among the different 
genotypes of STZ-treated mice (Fig. 3d). After the addition of the substrate NADPH and blockade with DETC, 
inhibition of superoxide production was similar in aortic rings from all of the STZ experimental groups (Fig. 3e), 
demonstrating similar SOD potential.
Constitutive exclusion of EDA domain increases NADPH oxidase activity selectively upregulating 
NOX4 expression in diabetic mice aorta. To further investigate the differences in vascular ROS gener-
ation induced by the constitutive exclusion of the EDA exon in EDA−/− diabetic mice, aortic superoxide anion 
generation was measured in the presence of substrates or inhibitors of NADPH oxidase, which is notably a crucial 
source of vascular ROS in diabetes. After incubation of aortic rings with NADPH, vascular superoxide produc-
tion increased (p < 0.05) in STZ-treated animals compared with respective control groups (Fig. 4a). However, 
the increase was more pronounced (p < 0.05) in aortas from STZ + EDA−/− mice suggesting an involvement of 
NADPH oxidase in the higher ROS production observed in this group. This finding was confirmed by normali-
zation of superoxide anion generation in STZ + EDA−/− after inhibition of NADPH oxidase by thioridazine, also 
in the presence of the substrate NADPH (Fig. 4b). To further characterize the contribution of NADPH oxidase to 
ROS generation, we investigated the expression of isoforms NOX1 and NOX4. In aortas from wild type mice STZ 
treatment increased NOX1 but not NOX4 protein expression (Fig. 4c,d and f). However, among diabetic animals, 
while NOX1 protein expression was not different among genotypes (Fig. 4c and f), both NOX4 protein and gene 
expression selectively increased (p < 0.05) in STZ + EDA−/− compared to STZ + EDAwt/wt and STZ + EDA+/+ 
(Fig. 4d,f and g). Similar effects were detected for the modulatory subunit p22phox (Fig. 4e,f and h).
Figure 3. Vascular oxidative stress is increased in aortas from diabetic (STZ+) EDA−/− mice with unchanged 
antioxidant potential. Quantitive analysis of aortic superoxide production by cytochrome c reduction (a) and  
by lucigenin-enhanced chemiluminescence (b); 3-nitrotyrosine levels in aortas from control (STZ− ) and diabetic 
(STZ+ ) mice aortas (c). Relative expression of the antioxidant enzyme CuZnSOD with representative blot  
(d); effect of the SOD inhibitor DETC (100 μ mol/l) on superoxide production in presence of NADPH (100 μ mol/l) 
(e). Data are normalized to parietal surface and represent at least 7 mice per group. a.u.: arbitrary units; 3-NT: 
3-Nitrotyrosine; BSA: Bovine Serum Albumin; RLU: relative light units; STZ: streptozotocin; SO: Superoxide 
Anion. *p < 0.05 vs other groups with same STZ treatment; #p < 0.05 vs. STZ- groups.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:37965 | DOI: 10.1038/srep37965
NOX4 is associated with increased TGF-β1 expression but not PKC activation in EDA−/− diabetic 
aorta, and is reversed by exogenous antioxidant administration. Since both protein kinase 
C (PKC) and TGF-β 1 pathways are known activators of NOX4 and play a role in the pathogenesis of diabetic 
vascular complications31,32, we explored their potential involvement in the selective upregulation of NOX4 in 
STZ + EDA−/− aortas. As expected, STZ treatment resulted in increased (p < 0.05) PKC activity and TGF-β 1 
gene and protein expression in aortas from wild type mice (Fig. 5a), but while in diabetic mice PKC activity 
was similar among all genotypes (Fig. 5b), TGF-β 1 gene expression increased (p < 0.05) in STZ + EDA−/− mice 
aortas compared to both STZ + EDAwt/wt and STZ + EDA+/+ (Fig. 5c). In a further set of experiments this change 
was prevented, also at protein expression level, by treatment for 12 weeks with the antioxidant n-acetylcysteine 
(NAC, Fig. 6a and e), indicating that oxidative stress is a major drive in diabetes-induced TGF-β 1 upregulation in 
STZ + EDA−/− mice. Furthermore, NAC treatment normalized also NOX4 and p22phox mRNA and protein levels 
in aortas from diabetic mice, resulting in the lack of differences among genotypes (Fig. 6b–d and f,g).
Figure 4. NADPH oxidase activity is increased and NADPH oxidase isoform NOX4 expression is 
selectively upregulated in diabetic (STZ+) aortas from EDA−/− mice. After stimulation with NADPH 
(100 μ mol/l) superoxide production increased in aortas from STZ + EDA−/− mice (a) and was normalized 
by incubation with the NADPH oxidase inhibitor thioridazine (10 μ mol/l), also in the presence of NADPH 
(100 μmol/l) (b). Densitometric analysis of NOX1 (c), NOX4 (d) and p22phox (e) protein expression in STZ- 
and STZ+ treated groups; representative Western blots in control and diabetic groups (f); NOX4 mRNA 
(g) and p22phox mRNA (h) in the same groups. Data represent at least 7 mice per group. Ex-vivo functional 
measurements are normalized to parietal surface. RLU: Relative Light Units; STZ: Streptozotocin; OD: Optical 
Density; SO: Superoxide Anion; a.u.: arbitrary units; *p < 0.05 vs other groups with same STZ treatment; 
#p < 0.05 vs. STZ- groups.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:37965 | DOI: 10.1038/srep37965
TRAF-6 expression is associated with eNOS modulation but not with TGF-β1 or NOX4 expression 
in EDA−/− diabetic aorta. Since EDA is a major endogenous ligand for TLR-4 we finally evaluated the 
protein expression levels of TRAF-6, an important TLR-4 classical signaling pathway mediator known to induce 
NF-κ B activation33. Western blot analysis of diabetic aortas showed increased TRAF-6 expression in diabetic 
EDA+/+ mice (Fig. 5d and f). Moreover, this finding was associated with the upregulation of GTPCH1 expression, 
the main enzyme involved in the synthesis of the NOS coupling factor BH4 (Fig. 5e and f), known to be increased 
after TLR-4-triggered NF-κ B activity34,35. However, no differences in both TRAF-6 and GTPCH1 expression 
levels were detected in STZ + EDA−/− compared to wild type (Fig. 5d–f).
Discussion
Impaired endothelium-dependent vasodilation and structural remodelling of the vessel wall, i.e. thickening of the 
subendothelial layer and accumulation of extracellular matrix proteins, are known features of diabetic vascular 
disease1,36. The fibronectin isoform containing the alternatively spliced EDA domain is normally absent from the 
circulation, but elevated plasma levels of EDA+ FN are found in diabetic patients16 and in other pathological 
conditions involving vascular disease37–41. Regulation of alternative splicing to generate the EDA + FN isoform is 
part of the response to hyperglycemia, and this appears to be potentially relevant and of great interest, as specific 
functions have been progressively identified for this domain4,11–13. However how EDA + FN might contribute to 
the modulation of endothelial dysfunction in diabetes is unclear.
This study provides evidence for a role of the EDA domain of FN in diabetes-associated endothelial dysfunc-
tion. STZ-induced diabetic mice devoid of the EDA exon (EDA−/− mice) showed increased endothelial dysfunc-
tion, suggesting a potential protective role of EDA + FN in the pathogenesis of the disease. Further experiments 
to identify the underlying mechanisms demonstrated that EDA + FN reduces vascular oxidative stress and pre-
vents eNOS uncoupling. To date, no interactions of EDA + FN with cellular pathways of endothelial dysfunction 
in diabetes have been described.
Vascular exposure to high glucose results in increased superoxide production and oxidative stress via vascular 
NADPH oxidase activation, mediated by the upregulation of the NOX1 and NOX4 isoforms42–44, which play a 
role in the development of diabetes-associated endothelial dysfunction22. However the contribution of NOX1 
to increased superoxide production and oxidative stress appears prominent compared to that of NOX4 dur-
ing diabetes43. In fact, apparently vascular NOX4 is not directly involved in diabetes-associated endothelial dys-
function43, but it may have indirect effects through protein-protein interactions and regulation of peroxynitrate 
formation23,24. Consistently with previous findings43, we found increased NOX1 expression after induction of 
diabetes with STZ in all genotypes, while NOX4 selectively increased only in EDA−/− diabetic mice. Accordingly, 
vascular superoxide generation and levels of oxidative stress marker nitrotyrosine were higher in aortas from 
Figure 5. Effect of diabetes on protein kinase C and TGF-β1 in aortas from experimental animals. Protein 
Kinase C (PKC) activity and TGF-β 1 mRNA relative increase in the aortas of wild type mice after STZ treatment 
(a); PKC activity (b) and TGF-β 1 mRNA levels in diabetic groups (c). Densitometric analysis of TRAF-6 (d) and 
GTPCH1 (e) protein expression in STZ-treated groups with representative blots (f). Data represent at least 7 
mice per group. STZ: Streptozotocin; OD: Optical Density; a.u.: arbitrary units; *p < 0.05; $p < 0.05 vs respective 
STZ- group.
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diabetic animals than in control group, but diabetic EDA−/− mice displayed the highest nitrotyrosine levels, 
a finding compatible with the highest NOX4 expression in this group24,42. The reason(s) for overexpression of 
NOX4 in STZ + EDA−/− diabetic aortas are largely unknown and, to date, no direct interaction between EDA 
and NOX4 has been demonstrated. Moreover, the finding of similar levels of NOX4 expression and activity in 
non-diabetic mice displaying different genotypes suggests that NOX4 overexpression during diabetes is selec-
tively linked to the lack of EDA domain. Mechanisms underlying diabetes-induced NADPH oxidase upregulation 
are complex and include the activation of signaling pathways such as protein kinase C and TGFβ 44,45. Altogether, 
these pathways promote extracellular matrix accumulation and the development of vascular complications in 
diabetes31,46,47. In our study PKC was similarly activated in all diabetic genotypes, excluding, therefore, its impli-
cation in NOX4 overexpression in vessels from diabetic EDA−/− mice. In contrast, TGFβ 1 mRNA was higher in 
EDA−/− compared with EDA+/+ and EDAwt/wt diabetic aortas. TGFβ selectively increases NOX4 (but not NOX1) 
expression and activity in several cell types, including fibroblasts, smooth muscle cells and liver stellate cells44. 
Treatment of experimental animals with the non-selective antioxidant n-acetylcysteine abrogated TGFβ , NOX4 
and p22phox upregulation. This finding is in line with recent studies, demonstrating that either ROS scavengers or 
selective inhibition of NOX4 modulate TGFβ activity48. The mechanisms underlying TGFβ 1 regulation by EDA+ 
FN are currently largely unknown. Since EDA is a well-known endogenous ligand of TLR44,8, one hypothesis is 
that TLR4 pathway might be involved in the observed results. Our findings show increased NOX4 expression 
and activity in the aortas of mice lacking EDA expression, suggesting for this finding a mechanism independent 
of NOX4 activation by direct interaction with TLR-4 as described by Park et al.49 Moreover, in our study we 
found that the expression of TRAF-6, an important TLR-4 signalling pathway mediator, was not modified in the 
aorta of diabetic EDA−/− compared to wild type, suggesting that also classical TLR-4 signalling via TRAF6 is not 
directly involved in the increase of reactive oxygen species observed in that group. Other mechanisms might 
therefore be implicated, potentially including the involvement of alternative modulatory pathways in the crosstalk 
between TLR-4 and TGFβ systems, as suggested by reports showing that TLR-4 activation downregulates TGFβ 
signaling via Smads in the microglia50. Moreover, since TGFβ 1 affects FN splicing by favoring the inclusion of 
EDA11,20, our data consistently support the possibility of a negative feedback loop between EDA + FN, TGFβ 1 
and NOX4 in diabetes, as previously suggested by Kawelke et al.51 in liver fibrosis between FN and TGFβ . In this 
Figure 6. Impact of antioxidant treatment with n-acetylcysteine (NAC) on aortic TGF-β 1 (a), NOX4 (b) and 
p22phox (c) protein levels, with representative blots (d). TGF-β 1 (e), NOX4 (f) and p22phox (g) mRNA levels 
in the same groups. Data represent at least 5 mice per group. OD: Optical Density; a.u.: arbitrary units; STZ: 
streptozotocin; *p < 0.05 vs. other groups; $p < 0.05 vs. respective NAC- group.
www.nature.com/scientificreports/
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setting, adequate amounts of EDA + FN are required to limit TGFβ 1 overexpression and activation51. In addition, 
reduced stimulation of TLR4 in EDA−/− mice resembles a situation similar to that described in TLR4−/− mice, 
also presenting endothelial dysfunction via upregulation of NADPH oxidase52,53. Further experiments will be 
required to better elucidate the complex network interplay which appear to underlie the effect of EDA on ROS 
production in diabetes.
Increased ROS formation by glucose-stimulated NADPH oxidase activation may either upregulate or down-
regulate antioxidant enzymes54. In our study, however, antioxidant activity did not differ among diabetic animals, 
suggesting that upregulation of NADPH oxidase in EDA−/− diabetic mice is selectively related to ROS forma-
tion and not to their scavenging via antioxidant mechanisms. Similarly, STZ-induced diabetes did not alter total 
eNOS protein in aorta in WT and EDA−/− mice. However, eNOS expression was decreased in EDA+/+ diabetic 
aortas, suggesting that EDA + FN, an isoform bearing a conformation that better exposes the RGD cell binding 
site recognized by the α 5β 1 integrin7, is more active in down-regulating eNOS gene expression than FN lacking 
the EDA domain. This hypothesis and our current findings are in agreement with previous results showing that 
plasma FN (which lacks the EDA domain) modulates eNOS gene and protein expression in a α 5β 1 integrin-Akt/
p38/MAP kinase dependent pathway in endothelial cells25, suggesting that EDA domain might be specifically 
involved in this process. Overproduction of superoxide anion reduces NO bioavailability by direct scavenging. 
In addition to NADPH oxidase, uncoupled eNOS is also a relevant source of superoxide in diabetic vessels2. 
By using L-NMMA-inhibitable superoxide formation to evaluate the contribution of uncoupled eNOS to total 
superoxide production we found that enzyme uncoupling did not contribute to ROS overproduction in diabetic 
aortas from either genotype; instead, a reduced enzyme uncoupling in aortas of STZ -EDA+/+ mice was suggested 
from available data. These results were confirmed by protein analysis, which showed that, in spite of reduced total 
eNOS protein, eNOS dimerization was increased in vessels from STZ + EDA+/+. These data, together with the 
observation that endothelial damage in STZ + EDA+/+ animals was similar to that of STZ + EDAwt/wt mice, sug-
gest that NO bioactivity in terms of NO and superoxide production is not fully reflected by levels of eNOS protein 
expression in these mice, as previously reported in diabetes22,55. Indeed, NADPH-derived superoxide can oxidize 
BH4 under physiological conditions and induce eNOS uncoupling24,56. However, diabetic uncoupling of eNOS 
due to NADPH-derived superoxide is mediated by NOX157, which was similarly activated in STZ + EDA−/− 
and in STZ + EDA+/+. Therefore, it is unlikely that this pathway is involved in the different enzyme coupling 
state observed among diabetic genotypes. Our data instead provide a mechanistic insight by showing that 
STZ + EDA+/+ mice present increased protein levels of the TLR-4 signalling mediator TRAF-6 in association 
with the upregulation of GTPCH1, the main enzyme involved in the synthesis of the NOS coupling factor BH4. 
Importantly, GTPCH1 expression is known to be increased in endothelial cells by enhanced NF-κ B activity, a 
main target activated by TRAF-6 signaling33,35. This pathway linking TLR-4 activation with enhanced GTPCH1 
expression has been recently fully described in macrophages34. While this mechanism remains mainly speculative 
until further investigation, these data are in excellent agreement with the hypothesis of EDA as a modulator of 
eNOS coupling in diabetic aorta via TLR-4.
Collectively, we showed a novel modulatory mechanism for endothelial dysfunction in diabetes. Lack of 
EDA + FN worsens endothelial function by increasing NADPH-oxidase NOX4 derived ROS production and 
TGF-β 1 expression. Conversely, EDA + FN lowers eNOS expression but, at the same time, compensates its poten-
tial lower activity by preventing eNOS uncoupling. Therefore, while on one side EDA + FN expands the extra-
cellular matrix resulting in diabetic structural vascular abnormalities, on the other side it prevents endothelial 
dysfunction by providing a feedback defence against excessive ROS generation. Modulation of FN alternative 
splicing might impact the course of vascular disease in diabetes.
Materials and Methods
Ethics statement. All experiments were performed in accordance with relevant guidelines and regulations 
issued by the European Parliament (Directive 2010/63/EU for animal experimentation). All experimental proto-
cols were approved by the board of the International Centre for Genetic Engineering and Biotechnology where 
the study was conducted.
Animals and Induction of Diabetes. We used male mice from two engineered mouse strains previously 
generated in our laboratory: the EDA+/+ strain, constitutively including the EDA exon and the EDA−/− strain, 
constitutively excluding the EDA exon26. Mouse strains were backcrossed with C57Bl/6 wild type (EDAwt/wt) 
for at least 6 generations. Diabetes was induced in mice, aged 12 weeks (n = 43 EDAwt/wt; n = 44 EDA+/+; n = 40 
EDA−/−) by intraperitoneal injection of streptozotocin (STZ, 50 μ g/kg body weight/day freshly dissolved in 0.1 M 
citrate buffer, pH 4.5, delivered for five consecutive days). Control mice were vehicle injected (n = 26 EDAwt/wt; 
n = 30 EDA+/+; n = 28 EDA−/−). A further subset of mice from each genotype was treated with STZ and the 
antioxidant N-acetylcysteine (NAC; 1.5 g kg−1 day−1 dissolved in drinking water58) was administered from week 
5 of diabetes (n = 10 NAC-EDAwt/wt; n = 9 NAC-EDA+/+; n = 11 NAC-EDA−/−). Diabetes onset was confirmed 
by blood glucose levels > 250 mg/dL (11 mmol/L) one week after the first dose of STZ using blood drawn by the 
tail vein. Animals not responding to STZ treatment were excluded. Mice were inspected daily, 5 h fasting blood 
glucose concentrations and body weight of STZ-treated animals were measured before treatment, one week later 
and then on a monthly basis. Control animals were measured before treatment and after 12 and 16 weeks. After 
16 weeks of diabetes, animals were anesthetized by intraperitoneal injection of avertin (20 μ l/g body weight, 
1.25% solution in PBS), blood was collected through cardiac puncture and aortas were harvested, cleaned of 
connective tissue and either used for analytical determinations or immediately frozen.
Hormonal and Metabolic Profile. Blood glucose was measured by reflectometry (AccuCheck, Roche, 
Indianapolis, IN, USA). Plasma lipids were measured by standard commercial colorimetric enzymatic assays 
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(BioMerieux, Marcy l’Etoile, France; Roche Diagnostics, Basel, Switzerland). Plasma insulin concentration was 
determined using a commercially available ELISA kit (DRG International Mountainside, NJ, USA).
Analysis of Vascular Reactivity. Isometric tension of mouse aorta was measured ex vivo in isolated 
organ baths, as previously described59,60. Briefly, rings (3 mm long) from each thoracic aorta were used for 
assessing vascular reactivity immediately after dissection. Rings were suspended in organ chambers filled with 
25 ml of gassed (95% O2 and 5% CO2) modified Krebs-Ringer bicarbonate solution (composition in mmol L-1: 
118.3 NaCl, 4.7 KCl, 2.5 CaCl2,1.2 MgSO4, 1.2 KH2PO4, 25.0 NaHCO3, 0.026 EDTA, 11.1 dextrose, pH 7.4). 
The rings were allowed to equilibrate for 1 h at 37 °C and then stretched to the optimal point as determined by 
repeated exposure to 20 mmolˑL−1 KCl. The maximal contraction of each ring was determined by phenylephrine 
(PHE) 10−5 molˑL−1. After washing and re-equilibration, submaximal contraction was then obtained using a 
10−6 molˑL−1 concentration of PHE. Dose-relaxation curves were finally performed by subsequent cumulative 
addition of acetylcholine (10−9 to 10−5 molˑL−1) or DEA-NONOate (2-(N,N-diethylamino)-diazenolate-2-oxide; 
10−10 to 10−5 molˑL−1) to the precontracted rings.
Protein expression analysis by Western Blot and ELISA. Proteins were extracted from the 
Tri-Reagent homogenates described below, after RNA extraction. Following ethanol mediated DNA precipitation 
and removal, proteins were collected by acetone precipitation, washed thrice with guanidinium hydrochloride 
solution (0.5 mol/l in 95% w/v ethanol), once with absolute ethanol and finally resuspended in SDS solution 
(1% w/v in ultrapure water) with protease inhibitors (P8340, Sigma, St.Louis, MI, USA). Samples were sepa-
rated by SDS-PAGE and Western blot analysis performed as previously described59,60. Equal load was checked 
by Ponceau S staining and GAPDH probing. Antibodies used in the present study as well as their dilution are 
described in Supplemental Table 1. Results from densitometric analyses are expressed as ratio between target pro-
tein and GAPDH optical densities. Low-temperature electrophoresis on 5% polyacrylamide gel (LT-PAGE) was 
performed for detection of eNOS dimer as reported22. Protein levels of TGF-β 1 were assessed by ELISA (Abcam) 
according to manufacturer’s recommendations.
Assessment of systemic and vascular redox state. Superoxide anion in intact aortic rings was measured 
by the SOD-inhibitable cytochrome c reduction assay as described59 and by low concentration (10 μ mol/l) 
lucigenin-enhanced chemiluminescence. eNOS- and NADPH oxidase derived superoxide and SOD activity 
in aortic rings were measured by addition of the following substrates or inhibitors: L-arginine (1 mmol/l), 
L-NMMA (100 μ mol/l), thioridazine (10 μ mol/l), diethyldithiocarbamate (DETC: 100 μ mol/l) and NADPH 
(100 μ mol/l). Data from incubated aortic rings was normalized by endothelial surface as measured (ImageJ) on a 
high-resolution scan of the opened vessel rings. Nitration of protein tyrosine in aortic tissue samples was meas-
ured by chemiluminescence enhanced indirect ELISA, as previously published59.
Quantitative Real Time PCR. Aortas underwent mechanical homogenization in Tri-Reagent (Sichim, 
Rome, Italy) followed by chloroform extraction and RNA precipitation in cold isopropanol. The resulting pellet 
was then washed with ethanol 70% (v/w) and resuspended in water. The purity of extracted RNA was checked by 
spectrophotometric determination (Nanodrop, Thermo Scientific, Wilmington, DE, USA) and its quality was ver-
ified in randomly selected samples by on-chip electrophoresis (2100 Bioanalyzer, Agilent, Santa Clara, CA, USA). 
All samples were treated with DNAse I (1 U/μ g RNA; Boehringer Mannheim, Mannheim, Germany) and reverse 
transcribed to cDNA using a commercially available kit (Taqman Reverse Transcription Reagents, Applied 
Biosystems). Quantitative real time polymerase chain reaction was performed on a real time scanner (ABI prism 
7900HT, Applied Biosystems) using TaqMan technology with custom designed primers and probes (Applied 
Biosystems; Eurofins MWG Operon). Primer and probe sequences used are shown in Supplemental Table 2. 
Relative quantification of gene expression was performed by interpolation of results on a standard curve of serial 
dilutions of a pool of samples and normalized by 28 S expression.
Protein kinase C activity. Protein kinase C activity in aortic rings was measured by a commercially available 
non-radioactive assay of peptidic phosphorylation (PepTag PKC assay, Promega, Madison, WI, USA) following 
manufacturer’s instructions.
Statistical Analysis. Statistical analysis was performed with SPSS (v.17) using t-test or ANOVA followed 
by post-hoc tests, for unpaired or for repeated measures as appropriate. Results from multiple comparisons were 
corrected according to Benjamini-Hochberg. Quantitative data are presented as the mean ± S.E. A p value < 0.05 
was considered statistically significant.
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